Business

Former Starbucks CEO Howard Schultz leaves Washington state for Florida

Published

2 hours ago

11 March 2026

Former Starbucks CEO Howard Schultz leaves Washington state for Florida

Check out what’s clicking on FoxBusiness.com.

Former Starbucks CEO Howard Schultz and his wife announced they’ve moved to Florida for their “retirement phase,” leaving Washington state after nearly half a century.

Schultz shared the news in a post on LinkedIn, recounting how he, his wife Sheri, and their golden retriever Jonas, made the move from New York City to Seattle 44 years ago.

“We were starting a new life,” Shultz wrote, recalling how Sheri would be their primary income earner as he started a new job “at a place called Starbucks” in September 1982.

Schultz would later become the coffee company’s CEO, serving in the position from 1986 to 2000, from 2008 to 2017, and as its interim CEO from 2022 to 2023.

STARBUCKS TO OPEN NEW OFFICE IN NASHVILLE, MOVE SOME JOBS FROM SEATTLE

CEO of Starbucks Howard Schultz speaking in Seattle

Howard Schultz, CEO of Starbucks, speaks during the company’s annual shareholders meeting in Seattle, Washington March 19, 2014. (David Ryder / Reuters Photos)

“The spirit of continuing forward has long underpinned our approach to life—in business, in philanthropy and most importantly, as a family,” Schultz wrote. “For those of you who know us well, we have entered the ‘retirement’ phase of our lives. (A term we are both just getting used to.)”

Starbucks founder Howard Schultz testifying before Senate

Former Starbucks CEO Howard Schultz testifies about the company’s labor and union practices during a Senate Committee on Health, Education, Labor and Pensions hearing on Capitol Hill in Washington, D.C., March 29, 2023. (SAUL LOEB/AFP via Getty Images)

Schultz added that he and Sheri moved to Miami, where they were enjoying the sunshine and being close to their kids on the East Coast as they raised their own families.

“We will be forever grateful for the memories made in Seattle and the relationships built along the way,” Schultz wrote. “To the family, friends and partners who made Seattle our home for so many years, thank you.”

STARBUCKS’ TURNAROUND PLAN SHOWS PROMISE IN US AS SALES GROWTH RETURNS FOR FIRST TIME IN 2 YEARS

Schultz has an estimated net worth of $3.5 billion, according to Forbes.

The news of Schultz’s move to Florida comes a week after Starbucks said it will be opening a new corporate office in Nashville.

A shot of a Starbucks store in Manhattan.

People pass by a Starbucks coffee shop in Manhattan, New York, on Jan. 15, 2025. (Mostafa Bassim/Anadolu via Getty Images)

Both announcements come as Washington state has been working to pass what has been dubbed the “millionaires tax,” which would impose a 9.9% income tax on households earning more than $1 million annually.

Ticker	Security	Last	Change	Change %
SBUX	STARBUCKS CORP.	100.77	+1.00	+1.00%

GET FOX BUSINESS ON THE GO BY CLICKING HERE

The Washington State House of Representatives passed the controversial bill in a 51-46 vote. The bill must now be confirmed by the State Senate before Democratic Gov. Bob Ferguson can sign it into law.

Business

Hershey introduces Dot’s original snack mix

Published

3 minutes ago

11 March 2026

NewsAdmin

Hershey introduces Dot’s original snack mix

Features a blend of Dot’s Original snack pieces.

Business

Medtronic plc (MDT) Presents at Leerink Global Healthcare Conference 2026 Transcript

Published

10 minutes ago

11 March 2026

NewsAdmin

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Medtronic plc (MDT) Leerink Global Healthcare Conference 2026 March 11, 2026 9:20 AM EDT

Company Participants

Thierry Pieton – Executive VP & CFO

Conference Call Participants

Michael Kratky – Leerink Partners LLC, Research Division

Presentation

Michael Kratky
Leerink Partners LLC, Research Division

All right. I think we can kick things off. But thank you all for joining. My name is Mike Kratky. I’m our Senior MedTech Analyst at Leerink and thrilled to be joined today by Medtronic’s CFO, Thierry Pieton. So thanks so much for joining.

Thierry Pieton
Executive VP & CFO

Yes. Thanks for having me.

Question-and-Answer Session

Michael Kratky
Leerink Partners LLC, Research Division

You just passed the 1-year mark at Medtronic. We’d love to maybe kick it off by hearing from your perspective, how the business has evolved over the last year. And as you look out over the next 12 months, what gets you most excited?

Thierry Pieton
Executive VP & CFO

Yes. Look, first of all, it’s been an interesting 12 months. I mean we’ve had a lot of things going on between sort of accelerating some of the new product launches and some of the portfolio actions that we’ve taken that I’m sure we’ll talk about, the IPO of MiniMed and we’re going back on offense in M&A, and we’ve done a couple of things in the last 3 or 4 months. So it’s been pretty busy. Look, I think the business has growing confidence.

I think a lot of the work that has been done for several years in the past few years to build the portfolio and to reinforce some of the operating mechanisms in the team and to work on R&D on some of the innovations that we’re launching now, it’s starting to pay off. And I think there’s a lot of excitement

Business

More support as heating oil costs 'double'

Published

17 minutes ago

11 March 2026

NewsAdmin

More support as heating oil costs 'double'

Rural farmers and homeowners are struggling to afford heating oil as prices rise.

Business

Outlook For Global Economy As Middle East Conflict Creates A Critical 'Chokepoint'

Published

23 minutes ago

11 March 2026

NewsAdmin

Outlook For Global Economy As Middle East Conflict Creates A Critical 'Chokepoint'

Business

Paro expands South Asian-inspired portfolio

Published

29 minutes ago

11 March 2026

NewsAdmin

Paro expands South Asian-inspired portfolio

Company adds lentil crisps to expand its lentil-focused product line.

Business

Apura Ingredients, New Tree Fruit Co. form partnership

Published

36 minutes ago

11 March 2026

NewsAdmin

Apura Ingredients, New Tree Fruit Co. form partnership

Partnership integrating NewTree’s “de-sugared” fruit technology into Apura’s portfolio.

Business

Rambus SVP, general counsel Shinn sells $404k in stock

Published

44 minutes ago

11 March 2026

NewsAdmin

Rambus SVP, general counsel Shinn sells $404k in stock

Business

Geox FY2025 presentation: net loss halved despite 8% sales decline

Published

50 minutes ago

11 March 2026

NewsAdmin

Geox FY2025 presentation: net loss halved despite 8% sales decline

Business

Total Energy Services Inc. (TOT:CA) Q4 2025 Earnings Call Transcript

Published

58 minutes ago

11 March 2026

NewsAdmin

Conference Call Participants

Josef Schachter – Schachter Energy Research Services Inc.
Tim Monachello – ATB Cormark Capital Markets Inc., Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome you to the Total Energy Services Fourth Quarter and Full Year 2025 Results Conference Call. [Operator Instructions] Thank you.

I would now like to turn the conference over to Mr. Daniel Halyk, President and Chief Executive Officer. Please go ahead.

Daniel Halyk
President, CEO & Director

Thank you, Krista. Good morning, and welcome to Total Energy Services Fourth Quarter 2025 Conference Call. Present with me is Yuliya Gorbach, Total’s VP, Finance and CFO. We will review with you Total’s financial and operating highlights for the 3 months ended December 31, 2025, and then provide an outlook for our business and open up the phone lines for questions. Yuliya, please go ahead.

Yulia Gorbach
VP of Finance & CFO

Thank you, Dan. During the course of this conference call, information may be provided containing forward-looking information concerning Total’s projected operating results, anticipated capital expenditure trends and projected activity in the oil and gas field industry. Actual events or results may differ materially from those reflected in Total’s forward-looking statements due to a number of risks, uncertainties and other factors affecting Total’s businesses and the oil and gas service industry in general. These risks, uncertainties and other factors are described under the heading Risk Factors and elsewhere in Total’s most recently filed annual information form and other documents filed with Canadian provincial securities authorities that are available

Business

Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Published

1 hour ago

11 March 2026

NewsAdmin

Xeris Biopharma Holdings, Inc. (XERS) Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDT

Company Participants

John Shannon – CEO & Director
Steven Pieper – Chief Financial Officer

Conference Call Participants

Jenna Davidner – Barclays Bank PLC, Research Division

Presentation

Jenna Davidner
Barclays Bank PLC, Research Division

All right. I think we’re all set.

Good morning. It’s still morning. Good morning, and welcome to the Barclays Miami Healthcare Conference. My name is Jenna Davidner. I’m one of the analysts here on the Specialty Pharmaceuticals team. And on stage with me, I have Xeris Biopharma. And from the company, we have the CEO, John Shannon. And on the end, we have Steve Pieper, the CFO.

Thank you, guys, for joining, and welcome to the conference.

John Shannon
CEO & Director

Thanks for having us.

Question-and-Answer Session

Jenna Davidner
Barclays Bank PLC, Research Division

So maybe just to level set the conversation, John, can you just give investors that are less familiar a brief overview of the company and your current product portfolio?

John Shannon
CEO & Director

Yes. I’ll just go really high level because I know we’re going to dig into some of this. So Xeris is a — it’s a fast-growing commercial biopharma company. We have 3 commercial products on the market, Gvoke for hypoglycemia. It’s a rescue pen for hypoglycemia, basically an EpiPen for diabetics.

Keveyis. Keveyis is for primary periodic paralysis, which is an ultra-rare hereditary genetic disorder. We can talk a little bit about that asset in a little bit. And then Recorlev. Recorlev is for hypercortisolemia and Cushing’s syndrome, which is our big grower in the business.

On top of that, we have XP-8121, which is our next potential blockbuster, and that’s a once-weekly subcu levothyroxine for hypothyroidism. And that’s Phase III ready. We’re going to get that